9887 — Nanjing Leads Biolabs Share News
0.000.00%
Last trade - 00:00- HK$8.06bn
- HK$7.04bn
- CNY177.26m
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer
Brief: Nanjing Leads Biolabs Says Lbl-024 Receives IND Approval From NMPA For Metastatic Colorectal Cancer
Brief: Leads Biolabs Announces Partner Oblenio Bio’S $62 Million Oversubscribed Series B Financing To Advance Tri-Specific T-Cell Engager Lbl‑051 For Autoimmune Diseases Into Clinical Development
Brief: Nanjing Leads Biolabs Instructs Trustee To Buy H Shares Up To $50 Mln Under H Share Award Scheme
Brief: Nanjing Leads Biolabs Says LBL-034 Granted Fast Track Designation By FDA
Brief: Nanjing Leads Biolabs Says LBL-024 Receives Orphan Drug Designation By European Commission
Brief: Nanjing Leads Biolabs Says LBL-024 (Opamtistomig, Pd-L1/4-1Bb Bispecific Antibody) Granted Fast Track Designation By U.S. FDA
Brief: Leads Biolabs And Dianthus Therapeutics Announce Initiation Of Phase 1 Trial Of LBL-047 (Dnth212) In Healthy Volunteers And Patients With Systemic Lupus Erythematosus
Brief: Nanjing Leads Biolabs Says LBL-047 Receives IND Approval From NMPA
Brief: Nanjing Leads Biolabs Announces Inclusion In MSCI Global Small Cap Indexes
Brief: Nanjing Leads Biolabs Signs Exclusive Global License Agreement With Dianthus
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable Of RMB166.4 MLN
China's Nanjing Leads Biolabs more than doubles in Hong Kong debut
Brief: Nanjing Leads Biolabs Reports Final Offer Price Of Hk$35/H Share